GeneTex
United States (US)

Bradykinin B1 receptor blocking peptide

Cat No. GTX88647-PEP

Application ELISA, Apuri, Blocking
Species Human
APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Dilution
ELISA Assay dependent
Apuri Assay dependent
Blocking Assay dependent
Not tested in other applications.

Specificity/Sensitivity

The peptide was used in the production of GTX88647.
PROPERTIES

Form

Lyophilized powder

Buffer

Lyophilized from 5% (v/v) acetonitrile/H₂O. Reconstitute pellet in 200μl distilled water to obtain a 0.5mg/ml peptide solution.

Note

For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

BDKRB1 blocking peptide , BKR1 blocking peptide , B1R blocking peptide , BRADYB1 blocking peptide , BKB1R blocking peptide , B1BKR blocking peptide

Background

Bradykinin, a 9 aa peptide, is generated in pathophysiologic conditions such as inflammation, trauma, burns, shock, and allergy. Two types of G-protein coupled receptors have been found which bind bradykinin and mediate responses to these pathophysiologic conditions. The protein encoded by this gene is one of these receptors and is synthesized de novo following tissue injury. Receptor binding leads to an increase in the cytosolic calcium ion concentration, ultimately resulting in chronic and acute inflammatory responses. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011]
Show More +

Research Area